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Botulinum neurotoxin type A (BoNT/A) paralyses muscles by blocking acetylcholine (ACh)
release from motor nerve terminals. Although highly toxic, it is used clinically to weaken
muscleswhosecontractionisundesirable,asindystonias.TheeffectsofaninjectionofBoNT/A
wear off after 3–4months so repeated injections are often used. Recovery of neuromuscular
transmission is accompanied by the formation of motor axon sprouts, some of which form new
synapticcontacts.However,thefunctionalimportanceofthesenewcontactsisunknown.Using
intracellular and focal extracellular recording we show that in the mouse epitrochleoanconeus
(ETA), quantal release from the region of the original neuromuscular junction (NMJ) can be
detected as soon as from new synaptic contacts, and generally accounts for >80% of total
release. During recovery the synaptic delay and the rise and decay times of endplate potentials
(EPPs) become prolonged approximately 3-fold, but return to normal after 2–3months. When
studied after 3–4months, the response to repetitive stimulation at frequencies up to 100Hz is
normal. When two or three injections of BoNT/A are given at intervals of 3–4months, quantal
release returns to normal values more slowly than after a single injection (11 and 15weeks to
reach50%ofcontrolvaluesversus 6weeksafterasingleinjection).Inaddition,branchingofthe
intramuscular muscular motor axons, the distribution of the NMJs and the structure of many
individual NMJs remain abnormal. These ﬁndings highlight the plasticity of the mammalian
NMJ but also suggest important limits to it.
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BotulinumtoxinA(BoNT/A)blockssignaltransmissionat
the vertebrate neuromuscular junction (NMJ). Although
highly toxic, it is used clinically in small doses which are
injected intramuscularly to inhibit undesirable muscular
contractions in various forms of dystonia and cerebral
palsy and also cosmetically to reduce facial wrinkling.
The blocking effect usually wears off after 3–4months so
repeated injections are required, sometimes over a period
ofyears,tomaintainthedesiredeffect(Jankovic&Hallett,
1994; Dolly & Aoki, 2006). As many people are now being
treated with BoNT/A, it is clearly important to under-
stand both its short-, and long-term effects on muscle
innervation.
BoNT/A is a metalloendoprotease. After binding to the
synaptic vesicle protein SV2 at the surface of the motor
nerve terminal (Dong et al. 2006), it is internalized and
activated.ItthenspeciﬁcallycleavesSNAP-25,anessential
protein in exocytosis, thus preventing the ‘quantal’ release
ofAChinresponsetonerveimpulses(Schiavoetal.2000).
DuringtheperiodofrecoveryfromBoNT/A,sproutsgrow
out from the motor axon and may make contact with the
muscle ﬁbre (Duchen, 1970; Angaut-Petit et al. 1990; de
Paiva etal.1999;Santafeetal.2000).Keysynapticproteins
aresubsequentlyexpressedatmanyofthesesites(Duchen,
1970; Yee & Pestronk, 1987; Juzans et al. 1996b;d eP a i v a
etal.1999).Althoughitisgenerallyassumedthatsynaptic
transmission occurs at these new contacts and mediates
the initial functional recovery from BoNT/A (e.g. Molgo
et al. 1990; Angaut-Petit et al. 1990) we are unaware that
this view has ever been directly tested.
Some evidence concerning the role of new contacts
in the recovery from BoNT/A comes from a study in
which changes in the ability of identiﬁed NMJs to take up
the membrane soluble ﬂuorescent dye FM1-43 (Cochilla
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et al. 1999) were studied in vivo at various times after
administering BoNT/A (de Paiva et al. 1999). Exposure
to BoNT/A blocked activity-dependent FM1-43 labelling
of the original nerve terminals within a few days. Newly
formed axonal sprouts were seen to take up FM1-43 at a
stageofrecoverywhenuptakebytheoriginalterminalwas
stillundetectable.However,2–3monthsafterintoxication,
the original terminal began to recover its ability to take
up the dye and the sprouts were then withdrawn. These
results were interpreted to mean that during the initial
stageofrecoverythesprouts,whichappearedtobetheonly
possible source of quantal ACh release, were exclusively
responsible for the initial recovery of neuromuscular
transmission.
The observations just described do not speciﬁcally
demonstrate ACh release. Indeed, it is uncertain that the
sensitivity of FM1-43 uptake experiments is adequate to
detect the low levels of quantal release that may be able to
excitemuscleﬁbresthathavebeenfunctionallydenervated
forsometime.Usingfocalextracellularrecording,capable
of detecting the effects of a single ACh quantum with
a spatial resolution of less than 10μm (del Castillo &
Katz, 1954), we have found that in the mouse ETA muscle
(Bradley et al. 1989), although quantal release from the
newly formed synaptic contacts does occur, substantially
morequantaarereleasedintheregionoftheoriginalNMJ
at all stages of recovery.
The action of BoNT/A is known to result in changes in
the kinetics of quantal release at some synapses (Sakaba
et al. 2005). In addition, there is evidence that types
of voltage-gated calcium channel that are not normally
expressed at mammalian NMJs are active during recovery
fromBoNT/A(Santafeetal.2000).Althoughanumberof
previous studies have noted an increase in the incidence
of ‘slow’ or ‘giant’ spontaneous mEPPs after exposure to
BoNT/A (Thesleff et al. 1983; Kim et al. 1984), little has
been reported about the properties of the evoked quantal
releasethataccountforfunctionalrecoveryoftheNMJ.We
havethereforeinvestigatedchangesinthetemporalaspects
of evoked ACh release and found that evoked responses
are also signiﬁcantly slower during the recovery from the
effects of BoNT/A.
Although multiple injections of BoNT/A are widely
used clinically to maintain muscle weakness, very little
is known about the ability of the NMJ to recover from
suchrepeatedexposure.Wehaveinvestigatedtheeffectson
NMJs in the mouse ETA of up to three injections, given at
successive intervals of 3–4months. Although there is sub-
stantialfunctionalrecoveryevenafterthreeinjections,this
recoveryissigniﬁcantlyslowerthanafterasingleinjection
and is associated with persisting structural abnormalities
of the terminal and preterminal motor axon.
Preliminary accounts of some of our observations have
been presented previously (Pang et al. 2002; Slater &
Rogozhin, 2006).
Methods
BoNT/A Administration
AllstudieswereauthorizedbyProjectLicencePPL60/3024
issued by the UK Home Ofﬁce and approved by the
Newcastle University Ethics Committee. A total of 180
mice were used in the study.
Allexperimentsweremadeontheepitrochleoanconeus
muscle(ETA),locatedsuperﬁciallyonthemedialaspectof
the proximal forelimb (Bradley et al. 1989). To expose the
muscle to BoNT/A, the mice were anaesthetized (3% iso-
ﬂurane) and a small incision (1mm) made in the skin in
the right axilla. Ten microlitres of a solution containing
0.5U of BoNT/A (BOTOX®, Allergan) in sterile saline
was injected under the skin over the ETA using a 10μl
Hamilton syringe ﬁtted with a 26 gauge needle. The skin
was closed with a single suture and 0.2ml Buprenorphine
(1:100, subcutaneous) given to control pain. At the time
of the acute experiment, the mice were killed by cervical
dislocation.
Nerve–muscle preparations
In the adult mice used (female, ca 30g) the ETA contains
about 400 muscle ﬁbres, each about 9mm long with a
meandiameterofabout35μm.Itisusuallyinnervatedby
ﬁve to seven motor neurons contained in a small branch
oftheradialnerve.Morethan90%ofthemuscleﬁbresare
‘fast’ as deﬁned by myosin heavy chain immunolabelling.
The results from mice injected with BoNT/A
were compared to those from uninjected mice, from
mice injected with 10μl of sterile saline (using the
same injection procedure outlined above), or from the
uninjected muscles contralateral to the experimental
muscles.
The experiments reported here were made on mice of
thestrainsCD1,MF1orTO. Nodifferencesintheresponse
to BoNT/A between the strains was noted.
Electrophysiological studies
Animals were killed at various times after BoNT/A
injection by stunning and cervical dislocation. ETA
nerve–muscle preparations were then dissected out and
maintained at room temperature (20–23◦C) in Liley’s
solution containing (mm): 137.8 NaCl, 4 KCl, 2 CaCl2,
1 MgCl2,1K H 2PO4, 12 NaHCO3, 11 glucose, gassed
with 95% O2–5% CO2 (Liley, 1956). The preparations
were pinned out in a recording chamber (Warner RC
27, Warner Instruments) with a volume of 2.5ml, lined
withSylgard(DowCorning).Acontinuousﬂowofgassed
bathing ﬂuid was maintained at 1mlmin−1 b yap e r i -
staltic pump. The muscle was viewed with a Leica DLFSA
ﬂuorescence microscope (Leica Microsystems) ﬁtted with
water immersion objectives (10–40×).
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The nerve was drawn up into a suction electrode
and routinely stimulated supramaximally with pulses of
0.1ms duration. Intracellular recordings were made with
glass electrodes (ca 10M  resistance when ﬁlled with
3m KCl), ampliﬁed by an Axoclamp 2B ampliﬁer (Axon
Instruments/Molecular Devices), further ampliﬁed and
processed (ﬁltered at 3kHz) by a CyberAmp 380 (Axon
Instruments), and digitized at a sampling rate of 41.6kHz
by a Digidata 1322A A/D converter (Axon Instruments)
before being displayed and saved using pCLAMP 9
software (Axon Instruments). Extracellular signals were
recorded with glass electrodes with an internal diameter
of 2μm, ﬁlled with bathing ﬂuid, and were ampliﬁed
by an AI402 head stage (Axon Instruments) feeding into
the CyberAmp (ﬁltered at 10kHz) and digitized as above.
Spontaneousevents(mEPPs)wererecordedincontinuous
samples of 1–2min duration.
The preparations were initially viewed in bright ﬁeld
transmitted light with a 2.5× dry objective with a long
working distance. Compound muscle action potentials
(CMAPs) were recorded during stimulation of the nerve
at 1Hz to provide an indication of the overall state of
functional innervation of the muscles before exposure
to labelling and blocking reagents (see below) (Fig. 1).
For this, an extracellular electrode (see above) was
positionedapproximately100μmabovethesurfaceofthe
muscle and moved parallel to the muscle ﬁbres until a
response was observed starting with an abrupt negative
deﬂection, indicating proximity to the innervation zone.
The electrode position was then further optimized by
moving it laterally to the position where the largest
response was observed.
Once CMAPs had been recorded, the motor axon
terminals were labelled with the ﬂuorescent dye
4-Di-2-ASP (Magrassi et al. 1987) (1μm, 10min;
Molecular Probes/Invitrogen, Paisley, UK) and viewed
with incident light using a ﬂuorescein ﬁlter block (Leica
I3).Neutraldensityﬁlterswereusedtoreducetheintensity
of the incident light, typically 8-fold, to limit damage
to the preparation from phototoxicity. Images of the
labelled NMJs were recorded with a CoolSnapHQ cooled
CCD camera (Photometrics), controlled by MetaMorph
software (Molecular Devices). Exposures were usually of
1s duration with the 40× objective.
Muscleactionpotentialswerethenblockedbyexposing
the muscles to μ-conotoxin GIIIB (μCTX, 2μm;P e p t i d e
Institute, Osaka, Japan) for 15min while the ﬂow was
stopped (Plomp et al. 1992). The toxin solution was then
suckedout,thepreparationreturnedtofreshbathingﬂuid
and the ﬂow resumed. This procedure blocked muscle
contraction for 45–60min, at which time the preparation
was re-exposed to the toxin.
After blocking contraction with μCTX, one or
two intracellular and two extracellular electrodes were
positioned approximately and the objective changed to
40× water immersion (2mm working distance) to search
for NMJs located on the surface of the muscle. To
recordsynapticpotentials,theintracellularelectrodeswere
inserted into the muscle ﬁbre 50–100μm away from
the NMJ, to minimize damage to the nerve terminal.
When two intracellular electrodes were used, current was
passed through one to maintain the membrane potential
close to −75mV. This ensured that measurements of the
amplitude and time course of synaptic events, which are
both inﬂuenced by the value of the membrane potential,
wereallmadeatnearlythesamemembranepotential.EPPs
were routinely evoked by trains of 100 stimuli delivered at
a frequency of 1Hz. In some cases, described in the text,
higher frequency trains were used. Spontaneous mEPPs
were recorded during continuous records of 1 or 2min
duration. The EPPs and mEPPs recorded in this way are
referredtobelowasEPPin andmEPPin todistinguishthem
from events recorded with extracellular electrodes.
Tomakefocalrecordingsofsynapticevents(delCastillo
& Katz, 1956) an extracellular electrode was positioned
closetoasiteofinterestalongtheaxonterminalorasprout.
Gentle pressure was then applied, under visual control, to
bring the electrode into contact with the axon without
causing damage (signalled by an abrupt increase in mEPP
frequency).
The response to nerve stimulation recorded from
a single extracellular electrode positioned near the
innervation zone in a muscle blocked with μCTX is the
sum of a diffuse ﬁeld potential from the summed EPPs
at a large number of NMJs, analogous to the CMAP, and
a much more localized response from the site of inter-
est, which we refer to here as EPPex. The ﬁeld response
varied little with movements of the electrode of even
100s of μm, but the local response was very sensitive
to movements of a few micrometres. To obtain the local
response without ‘contamination’ by the ﬁeld response, a
second extracellular electrode was frequently positioned
5–10μm away from the site of focal recording and the
signal from this reference electrode was subtracted from
the signal from the focal electrode (Katz & Miledi, 1965).
Successful placement of the focal electrode on the nerve
was indicated by the presence of a nerve action potential
in the average of a set of 25–100 responses (Angaut-Petit
et al. 1990).
In muscles that had been treated with BoNT/A, the
structure of the original NMJs was sometimes so altered
that they could not be identiﬁed with certainty. However,
ﬁbres with clearly identiﬁable original NMJs were used
when possible, to allow reliable comparison of events
associated with the new sprouts with those arising in
the region of the original NMJs. In these muscles, most
recordings from sprouts were made within 50μmo ft h e
original NMJs.
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Analysis of electrophysiological data
All electrophysiological recordings were analysed with the
Clampﬁt package in pCLAMP 9 (Axon Instruments).
Spontaneous events were extracted using the ‘template
search’ facility.
Kinetics of synaptic events. EPPex latency was deﬁned as
thetimefromtheonsetofthestimulusartefacttothetime
whenthepotentialreached20%ofitspeakvalue.Therise
time and decay time of synaptic events was deﬁned as the
time taken to go from 10 to 90%, or 90–10%, respectively,
of the peak amplitude.
Quantal content. The quantal content of the EPPin was
estimated from the ratio of EPPin amplitude to mEPPin
amplitude, after suitable correction of the signals for
membranepotentialandnonlinearsummation,assuming
a reversal potential of 0mV (Martin, 1955; Slater et al.
1992). No additional adjustment was made for the effect
of membrane capacity on quantal content (McLachlan &
Martin, 1981) (equivalent to setting their f =1).
Immunolabelling
Whole ETA muscles were incubated in
rhodamine–α-bungarotoxin (R-BgTx, 10−6 m; Molecular
Probes/Invitrogen) in Liley’s solution for 1h and then
washed thoroughly. They were then ﬁxed in 0.5–1%
paraformaldehyde in 0.1m phosphate buffer for 30min.
After washing in buffer, muscles were permeabilized
in alcohols (ethanol for 10min followed by methanol
for 10min, both at −20◦C) followed by incubation in
Triton X-100 (0.1%, 10min, room temperature). They
were then incubated overnight at 4◦C in a mixture
of rabbit anti-neuroﬁlament protein (NFP; AB1982,
Chemicon) and rabbit anti-synaptophysin (RB1461,
Neomarkers, Stratech), each at a dilution of 1/100, in
PBS containing 3% BSA (Sigma-Aldrich) and 0.1m
lysine (Sigma-Aldrich). The next day, after washing in
PBS, they were incubated for 3h at room temperature
in FITC–swine anti-rabbit (1/100) (DAKO) which had
been preincubated in half the volume of neat rat serum to
reduce non-speciﬁc binding. After washing overnight in
PBS, the muscles were mounted on slides in Vectashield
(Vector Laboratories).
Labelling of single teased muscle ﬁbres
To assess the distribution of differentiated postsynaptic
sites,muscleswerelabelledwithR-BgTx(10−6 m,1h)and
then ﬁxed in 1% paraformaldehyde 1h, 0.1m phosphate
buffer. After ﬁxation junctional regions, several milli-
metres long, of 30–50 individual ﬁbres from each muscle
studiedweredissectedoutandmountedinVectashieldfor
subsequent analysis.
Microscopy
Image recording. Fixed preparations and teased ﬁbres
were viewed with a Leica DMRA ﬂuorescence microscope
(Leica Microsystems) using ﬁlter blocks N21 (TMRITC)
and L5 (FITC, selective). Images were captured with a
SPOT-IIcamera(DiagnosticsInstruments)undercontrol
byMetaMorph.Whenappropriate,Z-serieswererecorded
at a spacing of 1 or 2μm using a 50× oil immersion
objective.
Image analysis. The area and number of regions of
postsynaptic differentiation were determined from teased
ﬁbres.Foreachﬁbre,eachofwhatappearedtobeseparate
regionsofhighR-BgTxlabellingwasoutlinedbyhand.The
regionsofhighR-BgTxlabellingatwhatappearedtobethe
original endplate, i.e. to consist of a closely packed cluster
of highly intense spots, were also outlined. The areas of all
regions were calculated using MetaMorph.
Statistical analysis and data presentation
Averaged data are presented with the s.d. and relevant
samplesize.Thesigniﬁcanceofdifferencesbetweenmeans
was determined using Student’s two-sided paired t test,
accounting for small samples where appropriate. The
relationship between number of BoNT/A injections and
rate of functional recovery, illustrated in Fig. 12, was
investigated using analysis of covariance (http://udel.
edu/∼mcdonanld/statancova.html).
Results
The initial aim of this study was to assess the contribution
of new synaptic contacts to the functional recovery of
mouseNMJsafterexposuretoBoNT/A.Beforedoingthis,
it was necessary to establish the time course of functional
recovery and axonal sprout outgrowth as it occurs in the
mouse ETA muscle, since this has not been previously
described.
Time course of recovery from a single injection of
BoNT/A
Neuromuscular transmission. Nerve-evoked contraction
of the ETA was fully blocked within 1–2days of BoNT/A
injection. The ﬁrst visible signs of recovery occurred
2–3weeks later, when weak contractions in response
to nerve stimulation could be seen. During the next
3–4weeks the contractions grew in strength and became
hard to distinguish from normal by eye. During the
period of impaired transmission, many muscles displayed
spontaneousﬁbrillation,inamannertypicalofdenervated
muscles. This was most prominent 1–4weeks after
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BoNT/A treatment. Occasionally spontaneous contra-
ctions were seen up to 4months after BoNT/A treatment
but not after that time.
To provide a more quantitative measure of the overall
recovery of function, compound muscle action potentials
(CMAPs)wererecorded(Fig.1A).IncontrolETAmuscles
these have a mean amplitude of 1.92mV (s.d. 0.48mV,
n=10). They were completely abolished within 1–2days
afterBoNT/Ainjection(Fig.1B).Duringrecovery,CMAPs
were ﬁrst detected at 2–3weeks, and some were within
the normal range of amplitudes 8–10weeks after BoNT/A
injection. Nonetheless, the CMAP amplitude was usually
less than normal even 10–12weeks after BoNT/A.
Figure 1. Recovery of CMAP after exposure of mouse ETA to
BoNT/A
A, recordings of CMAPs at representative times during the course of
recovery. B, changes in amplitude of negative peak of CMAP as a
function of time after exposure to BoNT/A. Each point represents a
single muscle. Open symbol on ordinate shows mean value for 10
control muscles ± S.D.
ToassessthechangesinquantalreleaseofAChfromthe
whole motor nerve terminal we used intracellular electro-
des to record EPPins and mEPPins. From their amplitudes
we calculated the quantal content (see Methods). These
values are shown, as a function of time after BoNT/A
injection, in Fig. 2. At NMJs in normal ETA muscles,
the quantal content in our conditions was 57.9 (s.d. 26.8,
n=10). The quantal content fell to <0.1 within 1–2days
afterBoNT/A.TheﬁrstNMJswheretheQChadincreased
to >1 were seen 12 days after injecting BoNT/A. By
6–7weeks after BoNT/A the QC was about 60% (33.2,
s.d. 13.1, n=3) of normal and after 10–14weeks was
indistinguishable from normal (61.6, s.d. 15.2, n=5).
The mean EPPin amplitude was signiﬁcantly correlated
withtheCMAPamplitudeinthesamemusclethroughout
the recovery period (r =0.92, n=53, P <0.001). This
implies that the experimental treatments used to record
EPPs(μCTX,4-Di-2-ASP)didnothaveadisproportionate
effect on, for example, quantal release early in recovery.
Mice of several strains were used in the course of this
project (see Methods). No differences between the strains
were observed in either the timing or extent of recovery.
Nerve sprouting and AChR accumulation. Afterexposure
to a blocking dose of BoNT/A, sprouts grow out from the
motoraxonterminalsandappeartoestablishnewsynaptic
contacts with nearby muscle ﬁbres (Duchen, 1970; Juzans
et al. 1996a;d eP a i v aet al. 1999; Santafe et al. 2000).
We investigated the process of axonal sprout formation
and differentiation to see how it was related in time to
the recovery of quantal release in the ETA. Muscles were
labelled with antibodies to NFP and synaptophysin to
reveal the nerves and their terminals and with R-BgTx to
visualize the distribution of postsynaptic AChRs.
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Figure 2. Recovery of evoked quantal release after exposure of
mouse ETA to BoNT/A
Quantal content of the EPPin, calculated from mean amplitudes of
mEPPins and EPPins (see Methods). Each point represents the mean of
values from approximately 10 NMJs in a single muscle. Open symbol
on ordinate shows mean value for 10 control muscles ± S.D.
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Axonal sprouts could be seen extending from the
motor axon terminals within a week or less of BoNT/A
injection (Fig.3A, ‘1–2weeks’). Over the next few weeks,
these sprouts grew further, primarily along the muscle
ﬁbres. From about 2weeks after BoNT/A injection, lateral
branches began to emerge from the main longitudinal
sprouts and then gradually increased in length. From an
earlystage,manyofthegrowingendsofthesproutsended
in roughly circular varicosities, typically about 3μmi n
diameter.
Figure 3. Axonal sprouting induced by exposure of mouse ETA
muscle to BoNT/A
A, images of terminal motor innervation at representative times during
recovery. Nerves labelled with antibodies to neuroﬁlament protein and
synaptophysin (green), AChRs in muscle labelled with R-BgTx (red).
The appearances illustrated in each panel are typical of those seen at
the indicated times after injection of BoNT/A. B, time course of events
in the response of NMJs to exposure to BoNT/A, expressed as the
fraction of NMJs (%) having the features shown. Sprouts form within
the ﬁrst week or so and AChR clusters appear a few days later. The
increase in quantal release is indicated by curves showing the fraction
of NMJs with QC > 5, representing an unambiguous increase from the
blocked level, and of NMJs with QC > 25, a value likely to cause
muscle ﬁbre excitation and contraction. Each point represents the
mean of values from 1–5 muscles.
Clusters of AChRs, adjacent to the growing sprouts,
were apparent from about 2weeks of BoNT/A injection
(Fig.3A, ‘2–3weeks’). Initially, these appeared as faint,
poorly deﬁned clusters lying along the sprouts. As the
lateralbranchesformed,mostoftheAChRclusterstookon
a circular, spot-like form, coincident with the varicosities,
and grew brighter and more clearly deﬁned (Fig.3A,
‘3–4weeks’). At times greater than 4weeks after BoNT/A
injection many of the AChR clusters had bright rims,
similar to those seen at normal NMJs, suggesting the pre-
sence of a concave depression in the surface of the muscle
ﬁbre at the new synaptic sites (Fig.3A,‘ >4weeks’). At no
timeintheformationandmaturationofnewcontactswere
AChR clusters seen that were not close to axon sprouts.
We quantiﬁed the incidence of sprouts and AChR
clusters after BoNT/A intoxication in order to relate their
appearancetotheonsetofevokedquantalrelease(Fig.3B).
Atapopulationlevel,theAChRclustersformabout5days
after the formation of sprouts. A clear increase in quantal
content, represented by the fraction of NMJs where the
quantal content has increased to >5 (normal value 58), is
presentat50%ofNMJsbyaboutaweekafterAChRclusters
form.Totriggeramuscleactionpotentialandcontraction
probably requires the release of about 25 quanta (based
on data from rat soleus muscles; Wood & Slater, 1997).
As shown in Fig.3B, this level of release occurs at 50% of
NMJs by about 40days after BoNT/A.
Insummary,ourobservationsoftheETAconﬁrmearlier
observations (de Paiva et al. 1999) that after an injection
of BoNT/A, well formed axonal sprouts whose terminals
are associated with AChR clusters are already present for
severaldaysbeforequantalreleaseofAChbecomesreadily
detectable. However, the entire recovery process occurs
more rapidly in ETA than in the mouse soleus, extensor
digitorum longus or levator auris (LAL) (Duchen, 1970;
Tonge, 1974; Santafe et al. 2000). We have conﬁrmed the
slower recovery in soleus (L. Gurney, K. K. Pang & C. R.
Slater, unpublished observations).
How much do new synaptic contacts contribute to
functional recovery?
To estimate the contribution of new synaptic sites to
the initial recovery after exposure to BoNT/A, we ﬁrst
located individual new synaptic sites and then estimated
theintensityofreleasefromthem.Wethendeterminedthe
extent and number of such new synaptic contacts. Finally
we used these data to estimate the summed contribution
of release from all the new sites on a muscle ﬁbre to the
total quantal content.
Location of release sites. The spatial resolution of intra-
cellular recording does not allow quanta released from
new synaptic sites to be easily distinguished from those
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releasedfromthesiteoftheoriginalNMJ.Tostudyrelease
from new sprouts, we therefore used focal extracellular
recording (del Castillo & Katz, 1954), which allows the
sites of synaptic current generation to be deﬁned with a
resolution of 5–10μm.
The nerve–muscle preparations were routinely labelled
withthemitochondrialdye4-Di-2-ASPtoallowthenerve
anditssproutstobevisualizedduringelectrophysiological
recording (Magrassi et al. 1987). Normal nerve terminals
labelledwiththisdyegenerallyappearasacompactcluster
of discrete varicosities, each typically 2–3μm in diameter
(Fig. 4). Extracellular electrodes placed near such labelled
spots frequently record both spontaneous and evoked
quantal events which we refer to as EPPex. Comparison of
recordsfromtwoelectrodesplacedatdifferentspotsatthe
same normal NMJ conﬁrms that this mode of recording
can differentiate between quanta released from sites less
than 10μm apart (Fig. 4).
Axonal sprouts induced by BoNT/A are also labelled
by 4-Di-2-ASP (Fig.5A) (cf. de Paiva et al. 1999). Like
normalnerveterminalstheyappearasanumberofdiscrete
varicosities, but ones that lie outside a region bounded by
a smoothly contoured line enclosing the original nerve
terminal. Such a line is shown in Fig.5A. In the later
stages of recovery from BoNT/A, recordings of evoked
and spontaneous quantal release could almost always be
obtained when the electrode was placed over such spots
(see below), conﬁrming that they correspond to discrete
sites of quantal release along the sprouts. Movements of
the electrode of only a few micrometres away from these
spots resulted in a great reduction in the amplitude of the
spontaneousevents.Atthesametime,theamplitudeofthe
evoked responses was reduced to a level that was relatively
independent of position. This ‘ﬁeld’ signal, analogous to
the CMAP, represents the effects of the summed end-
platecurrentsfrommanyNMJs.Weoftenplacedasecond
extracellular electrode near the ﬁrst to record this ‘ﬁeld’
EPP so that it could be subtracted to reveal the ‘speciﬁc’,
position-dependentresponses(cf.Fig.5B)(Katz&Miledi,
1965).
During the initial recovery phase, 2–6weeks after
BoNT/A, synaptic events could be recorded with an
extracellularelectrodebothatthesitesoftheoriginalNMJs
and at varicosities on sprouts (Fig.5B). In this ﬁgure, the
six to eight responses shown were selected from series of
100 trials to illustrate the range of amplitudes, and do not
necessarilyrepresenttheaverageresponses(seebelow).In
general, synaptic activity was always easier to record from
the original NMJs than from the sprouts. However, this
effect is difﬁcult to quantify because at many spots it was
necessary to reposition the recording electrode repeatedly
before synaptic events were detected. Thus the absence
of detectable events at any particular recording site was
not always a good indication of an absence of quantal
release. On the other hand, even a single recorded event,
as illustrated in Fig.5B ‘New’, is clear evidence that the
electrode is adequately placed to record synaptic events.
An important additional indication that the recording
electrode was placed over a sprout was the ability to
record an extracellular nerve action potential (Brigant &
Mallart, 1982; Mallart & Brigant, 1982; Angaut-Petit et al.
1990). The detection of these signals was improved if the
electrode was pressed against the sprout. However, this
riskedcausingmechanicaldamage.Wethereforegenerally
looked for the nerve action potentials in averages of
25–100 traces. Only when both 4-Di-2-ASP labelling and
anextracellularnerveactionpotentialwerepresentwasthe
absenceofdetectablesynapticeventstakenasasigniﬁcant
negative ﬁnding.
Assessment of release. Early in recovery only occasional
stimuli evoked detectable responses at any extracellular
recordingsite(Fig.5B).Forexample,attheNMJillustrated
Figure 4. Spatial discrimination of focal extracellular recording
A, a ﬂuorescence image of an ETA NMJ after labelling with 4-Di-2-ASP
merged with a bright ﬁeld image showing muscle ﬁbre and electrodes.
Two extracellular electrodes (‘Ex 1’ and ‘Ex 2’) are positioned on
different parts of the nerve terminal, 8.9 μm apart. The position of the
two intracellular electrodes (‘V’ and ‘I’), both slightly out of focus in
this image, are indicated by arrows. Electrode ‘V’ is used to record
membrane potential and electrode ‘I’ is used to pass current to
maintain membrane potential near −75 mV. B, the bottom trace
shows mEPPs recorded with the intracellular electrode (‘V’) and the
other two traces show recordings by the two extracellular electrodes.
The difference in the recordings from these two electrodes gives an
indication of the spatial resolution of this approach.
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inFig.5,21daysafterBoNT/A,responsesfromtheoriginal
NMJ were seen in 28/100 trials and in only 1/100 trials at
the ‘new’ site. In contrast, EPPins were recorded in 82/100
and 84/100 in these two series of trials.
The very low frequency of spontaneous mEPPexs
observedmadeitimpracticaltoestimatedirectlythemean
number of quanta released by a single nerve impulse from
new synaptic spots. Instead, we made the assumption
that during the early stages of recovery, as in many other
situationswherequantalcontentislow,thereleaseprocess
obeyed Poisson statistics (Katz, 1969). Analysis of the
distributionofamplitudesofEPPexssuggestedthatthiswas
avalidassumption.Forexample,attheNMJillustratedin
Fig. 5, the series of 100 trials recorded from the ‘original’
site included 72 ‘failures’, i.e. stimuli that failed to evoke
a detectable response, 24 responses whose amplitude was
intermediate in amplitude (mean 0.15±0.024mV) and
fourresponseswhoseamplitudewasclearlygreater(mean
0.27±0.030mV). The Poisson distribution predicts that
for a failure rate of 72%, 24% of the responses should
consistof1quantumand4%of2.Inthiscase,theobserved
distribution of EPPex amplitudes agreed well with that
predicted by the Poisson distribution for a mean quantal
content of 0.33.
We therefore used the fraction of response ‘failures’ to
estimatethemeannumberofquantareleasedinthepickup
area of the electrode. We deﬁned this value as the ‘local’
quantal content (QClocal), i.e. the mean number of quanta
detectedbytheextracellularelectrodeatagivenrecording
siteinresponsetoasinglestimulus.Aninherentlimitation
Figure 5. Localization of evoked quantal
release
A, image of nerve terminal, labelled with
4-Di-2-ASP, from mouse ETA 21 days after
exposure to BoNT/A. Two extracellular recording
positions are indicated, one over part of the
original terminal and one over a newly formed
synaptic spot about 10 μm away. The limits of
what is considered the original terminal are
shown by a continuous white line. B, recordings
from the two sites depicted in A. For each site
the upper traces are from the extracellular
electrode, with downward deﬂections indicating
evoked synaptic currents. The lower traces are
from an intracellular electrode. Six pairs of
traces, which were selected from a series of 100
to show the range of values observed, are
shown for each site. One pair from each site has
been shown in grey. At each site most stimuli
failed to evoke any localized extracellular
response even though an EPPin was present. At
the ‘new’ site the trace in grey was the only
clear response seen in 100 trials. Further details
in text.
of this method for estimating QClocal is that it can only be
usedwhenthefractionoffailuresisgreaterthanabout5%.
This was generally the case up to 6–8weeks after exposure
to BoNT/A.
Comparison of the QClocal at original and new synaptic
sitesshowsthatattheearlieststagesoffunctionalrecovery,
2–3weeks after exposure to BoNT/A, more quanta were
released by a single nerve action potential at recording
sites at the original NMJ than at the new synaptic spots
(Fig. 6). This situation was maintained for at least
2months, by which time overall recovery of quantal
release was more than 50% complete. During the period
2–12weeksafterexposuretoBoNT/A,themeanQClocal at
‘new’ synaptic spots was 17% (s.d. 19%, n=10 muscles)
of that from sites in the original junctional region.
Extentofnewsynapticcontacts. Toestimatethesummed
contributionofquantalreleasefromnewsynapticcontacts
to the overall quantal content at recovering NMJs, we
needed to establish the spatial extent and number of the
newsynapticregions.Todothiswedeﬁnedandmeasured
all the regions of high AChR density, marked by labelling
with R-BgTx, on individual ETA muscle ﬁbres teased
from muscles at various times after exposure to BoNT/A.
Examplesofmuscleﬁbresindifferentstagesofrecoveryare
showninFig.7A.Intheexamplefrom14days,whenmost
NMJs have many axonal sprouts, no new AChR clusters
have formed. In the example from 17days, faint, poorly
deﬁnedclusterscanbeseenupto75μmfromtheoriginal
NMJ. By 24days, the AChR clusters are much brighter
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and are more clearly deﬁned. We traced around each of
these AChR clusters and then measured its area. Most
individual AChR ‘spots’ are 3–5μm in diameter. Often,
a number of spots were close enough to each other so that
their boundaries were hard to resolve. In these cases, we
tracedaroundaclusterofcontiguousspots.Wereferbelow
to a ‘region’ of high AChR density as a spot or a collection
of spots so close together that they were included in the
same measuring proﬁle.
The total area of new synaptic contacts on a given ﬁbre
was generally substantially less than that of the original
NMJ (Fig.7B). During the ﬁrst 3weeks after BoNT/A
injection, the total area of new contacts per muscle ﬁbre
increasedtoabout70μm2 andthenremainedatthatlevel
(mean 67.5 μm2, s.d. 33.6, n=15 muscles, for the period
3–7weeks). In contrast, original NMJs have an area of
218μm2 (s.d. 35.0, n=15). Thus, during most of the
recovery phase, the area of the new contacts was about
30% of that of the originals, or about 25% of the total
area of high AChR density per muscle ﬁbre. The mean
number of contiguous regions of AChR labelling during
the period 3–7weeks after BoNT/A was 4.95 (s.d. 2.05,
n=8muscles)permuscleﬁbre(Fig.7C),givinganaverage
area of such regions as 13.6 μm2. This analysis shows that
in the majority of muscle ﬁbres, the area of new synaptic
contacts remained a relatively small fraction of the total
synaptic area.
Contribution of new synaptic contacts to functional
recovery. We estimated the quantal content from new
contacts by assuming that our extracellular recordings
detected quanta from a single region of new synaptic
contact. This seemed justiﬁed because the average area
of these regions (13.6μm2) is well within the pickup area
of the extracellular electrodes (100–300 μm2), and there
was generally a distance of at least 10μm between these
regions(cf.Fig.7A;17and24days).Onthisbasis,thetotal
quantal content is given by the product of the number
of regions per muscle ﬁbre and the local quantal content.
WhennewAChRclusterswereclosertogetherthan10μm,
this procedure would tend to overestimate release from
new spots. The resulting values are shown in Fig. 8, in
which data have been pooled into bins 5days wide.
From the earliest time when recovery of quantal release
can be reliably detected, the total number of quanta
released from new synaptic contacts is substantially less
than from the sites of the original NMJs. On average,
throughout the ﬁrst 6weeks after BoNT/A, release from
new contacts was 17% of that from original NMJs (s.d.
19%, n=10).
Temporal features of evoked synaptic events during
recovery
In the course of our studies it became clear that there
were signiﬁcant changes in both the latency and time
course of the evoked synaptic responses at NMJs during
the process of recovery from BoNT/A. Since it is known
that cleavage of SNAP-25 by BoNT/A inﬂuences the
dynamics of quantal release at other synapses (Sakaba
et al. 2005), we attempted to deﬁne these changes in more
detail.
Latency and synaptic delay of evoked synaptic events
during recovery from BoNT/A. In a previous study, made
on the LAL muscle of mice, it was found that the
latency of EPPs increased during recovery from BoNT/A
(Santafe et al. 2000). The latency of the EPP has two
components: the conduction time in the nerve and the
synapticdelaybetweenthearrivalofthenerveimpulseand
detectable quantal release. To distinguish between these
factorsasdeterminantsoftheincreasedlatency,westudied
EPPexs. During the ﬁrst 30days after BoNT/A, the average
latency from stimulus to onset of EPPex was nearly twice
as long as normal (control, 1.1±0.13ms, n=5 versus
BoNT/A, 1.9±0.33ms, n=23, P <0.0001) (Fig.9A
and B).
The conduction velocity along sprouts evoked by
BoNT/AinthemouseLALhasbeenreportedas0.24ms−1
(Angaut-Petit et al. 1990), a value not far from that
originallymeasuredatnormalfrogmotornerveterminals
(0.3ms−1) (Katz & Miledi, 1965). In the ETA, in muscles
up to 36days after BoNT/A, we observed a value of
0.17ms−1 (s.d. 0.08, n=8). Few of the sprouts we
studied were more than 100μm long (see Santafe et al.
2000). For a sprout of that length, assuming a conduction
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Figure 6. Comparison of the intensity of evoked quantal release
at new and original synaptic sites during recovery of mouse ETA
NMJs from exposure to BoNT/A
The local quantal contents (QClocal) of the extracellular responses to
nerve stimulation, calculated from the fraction of ‘failures’ using the
Poisson distribution (see text for further details), are shown as a
function of time after exposure to BoNT/A. Each point represents the
mean of values from 1 to 27 (mean 18) ﬁbres in 2–8 (mean 5) muscles
at times < 40 days, and 1–2 muscles for times > 40 days, pooled into
5-day intervals after exposure to BoNT/A.
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Figure 7. Extent of AChR clusters at new synaptic spots that
form during recovery of mouse ETA muscles after exposure to
BoNT/A
A, images of AChRs, labelled with R-BgTx, at representative times
during recovery. Arrows point to new synaptic spots. At 17 days these
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Figure 8. Estimated contribution of quantal release from new
synaptic spots to neuromuscular transmission during recovery
from exposure of mouse ETA to BoNT/A
Open symbols, total quantal content recorded with an intracellular
electrode; ﬁlled symbols, estimated quantal release from all new
synaptic spots on individual muscle ﬁbres (see text). Points represent
mean values from 1 to 8 (mean 3.4) muscles, pooled into 5-day
intervals after exposure to BoNT/A. Typically 2–3 ﬁbres were studied in
detail in each muscle. Note that at all times, the estimated
contribution from new synaptic sites is a small fraction of the total.
velocity of 0.2ms−1, the conduction time along the entire
sprout would be 0.5ms. While it is thus likely that the
conductiontimeaccountsforsomeoftheincreasedlatency
at new synaptic sites on the longest sprouts, we observed
no signiﬁcant difference between the observed average
latencies at sites on sprouts (1.9±0.48ms, n=5) and at
thesiteoftheoriginalNMJ(1.9±0.26ms,n=18)during
the period up to 30days after exposure to BoNT/A.
In contrast, we found clear evidence for an increase in
the second component of EPP latency, the synaptic delay.
We deﬁned this as the time from the negative peak of the
nerveactionpotentialtothefootoftheEPPex (Fig.9C).At
those NMJs where both a clear nerve action potential and
EPPex were recorded, the synaptic delay increased from a
normalvalueof0.32±0.034ms(n=8)to0.73±0.16ms
(n=26 NMJs studied up to 30days after exposure to
BoNT/A, P <0.0001). There was no signiﬁcant difference
between the delays observed at new and original sites
(0.70±0.14ms, n=6 versus 0.74±0.17ms, n=20).
Thus, during recovery from BoNT/A, the events coupling
are fainter and less well-deﬁned than at 24 days. B, total area, per
muscle ﬁbre, of AChR clusters at original NMJs and at new synaptic
sites as a function of time after exposure to BoNT/A. At all times the
area of new sites is substantially less than that of the original NMJs. C,
mean number of separate regions of high AChR density on individual
muscle ﬁbres as a function of time after exposure to BoNT/A. Each
point represents the mean of data from 1 to 4 muscles pooled into
5-day intervals after exposure to BoNT/A.
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nerve terminal depolarization to quantal release occur
more slowly than normal.
Kinetics of synaptic potentials during recovery. During
the early stages of recovery of transmission, evoked
synaptic potentials with an unusually slow time course
were sometimes seen (Fig. 10). Some of these recalled
the ‘giant’ or ‘slow’ spontaneous miniature potentials
previously described by others (Thesleff & Molgo, 1983;
Thesleff et al. 1983; Kim et al. 1984). In those earlier
studies, changes in the time course of evoked events were
not reported.
A systematic study of the time course of individual
EPPins showed that during the initial recovery process,
both the rise and decay times were substantially
longer than normal (Fig.10A and B). In the period
12–22days after exposure to BoNT/A, the rise time
of EPPins was 1.61±0.20ms (control 0.53±0.015ms,
P =0.0014) and the decay time was 15.07±1.87ms
(control 4.52±1.19ms, P =0.0002). The mean values
for individual muscles were highly signiﬁcantly correlated
(P <0.001).Theperiodofprolongedkineticslastedabout
4weeks, and was followed by a return to normal values
about6weeksafterexposuretoBoNT/A(Fig.10C andD).
Thus,theaveragekineticpropertiesoftheEPPinsreturned
tonearnormalvalueswhenthemeanquantalcontentwas
about25,stilllessthanhalfitsnormalvalue.Thissuggests
thatthechangesinEPPintimecourseatindividualsynaptic
sites are short-lived.
Of particular interest were a small number of ﬁbres
where more than one population of EPPins, differing in
time course were present (Fig.10E–H). Figure10E shows
most of the 71 events evoked during a series of 100 trials
from one of these ﬁbres. Of the 100 responses, 29 were
‘failures’, indicating that the quantal content of the EPPin
was 1.24. Of the events that were evoked, 52 were ‘pure
fast’ (e.g. Fig.10F), 7 were ‘pure slow’ (Fig.10H) and
12 were ‘mixed’ (Fig.10G), apparently the sum of a fast
and a slow response. Thus 64 responses included a fast
response and 19 a slow response. If the responses of these
two classes arose independently, the probability that both
a fast and a slow response would appear in the same
trial is 0.64×0.19=0.12. This predicts that 12 responses
should be mixed, whereas 11 were observed. The results
of this analysis thus support the view that the two classes
of response at this and several other similar NMJs were
evokedindependently.Unfortunately,theseﬁbresweretoo
rare to allow detailed analysis of the sites of origin of the
two different classes of evoked response.
Response to repetitive stimulation. Theresultsdescribed
so far relate to NMJs stimulated at 1Hz. As a further
test of the recovery of quantal release, in conditions more
related to normal functioning, we studied the response
Figure 9. Temporal changes in onset of evoked responses
during recovery from BoNT/A
A, records showing averaged EPPexs recorded from a control NMJ,
from new synaptic contacts 16 days after exposure to BoNT/A and
from the site of an original NMJs 21 days after exposure to BoNT/A. B,
changes in EPPex latency (time from stimulus artefact to 20% of peak
amplitude of EPP). C, changes in synaptic delay (time from negative
peak of nerve action potential to 20% of peak amplitude of EPPex).
Note that the time course with which both latency and synaptic delay
approach normal values is similar at the new contacts and at the
original NMJs. Each data point represents averaged data from one
recording site.
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Figure 10. Changes in kinetic properties of EPPins during recovery from exposure of mouse ETA muscles
to BoNT/A
All recordings show EPPins selected from trains of 100 stimuli (1 Hz). A, typical EPPs (14 superimposed) from
uninjected muscles. Note minimal variation of amplitude or time course. B, superimposed EPPins from ETA injected
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to repetitive stimulation in some muscles 4months
after exposure to BoNT/A. Over the frequency range of
1–100Hz, the properties of release at NMJs exposed to a
single injection at BoNT/A were qualitatively similar to
normal (Fig. 11). At frequencies below 50Hz there was a
depression of release during a train of 100 stimuli. This
included both a rapid phase consisting of the ﬁrst 20 or so
responses followed by a much slower phase. At 50 and
100Hz, these two phases of depression were preceded
by a brief phase of potentiation. This resulted in EPPins
amplitudesabout1.2timestheinitialvalueatbothtreated
and control NMJs.
Recovery from multiple injections of BoNT/A
Recovery of neuromuscular transmission. It is clear from
clinicalexperiencethatsomedegreeoffunctionalrecovery
is possible even after multiple injections of BoNT/A.
However, we are unaware of any reports of systematic
studiesoffunctionalrecoveryofquantalreleaseaftermore
than one exposure to BoNT/A. We therefore investigated
the recovery of quantal content in the ETA muscles after
two and three injections, given at intervals of roughly
3–4months (Fig. 12). In each case, the standard BoNT/A
injection initially caused a rapid and profound block of
quantal release.
Quantal release recovered signiﬁcantly after both two
and three injections, but more slowly than after a single
injection. The slope of the regression line for recovery
after a single injection was 0.89 quantal units day−1.T h e
slopesoftheregressionlinesforrecoveryaftertwoorthree
injectionswerenotsigniﬁcantlydifferentfromeachother.
When these data were pooled, the slope of the regression
for recovery after more than one injection was one-third
of that for recovery after a single injection (0.30 quantal
units day−1). On the basis of these regression lines, the
time for the quantal content to reach 50% of its normal
value (57.9) was 43days for one injection, 74 for two and
105 for three.
The statistical strength of these conclusions was tested
using ANCOVA. The outcomes of this analysis are: (1)
the regressions of the three groups (1, 2 and 3 injections)
are not homogeneous (P =0.018), (2) the regressions of
the data for two and three injections are not signiﬁcantly
21 days previously. Note great variation of both amplitude and time course, and much smaller amplitude than
in control. C and D, changes in mean value of EPPin rise time (C, ‘RT’) and decay time (D, ‘DT’) during recovery
from BoNT/A. The total quantal content is shown in each graph for comparison. Note that the kinetic properties
of the EPPin return to normal values when the total quantal content has only reached approximately one-third of
its normal value. E, variable time courses of EPPins recorded from the same muscle ﬁbre, 15 days after exposure to
BoNT/A. EPPins of two quite distinct time courses could be recorded from this ﬁbre. Examples of these are shown
in F (fast EPPins), G (mixed time-course EPPins) and H (slow EPPins). A single response showing both fast and slow
components is highlighted in G.
different, (3) the regression of the data for one injection is
signiﬁcantlydifferentfromthatforeithertwo(P <0.0001)
or three (P <<0.0001) injections, and (4) the regression
of the data for one injection is signiﬁcantly different from
that for the pooled data for two and three injections
(P <<0.0001). It is thus clear that in these experiments,
recovery of evoked quantal release after an injection of
BoNT/A was signiﬁcantly slower in those mice that had
received one or two previous injections.
Structural abnormalities persist after multiple BoNT/A
injections. Although no systematic studies have been
made, available evidence indicates that structural
abnormalities of motor innervation persist in humans
for years after the last of a series of BoNT/A injections
(Alderson et al. 1991). We were therefore interested to
see whether NMJs in the mouse ETA whose function
had recovered after two or three BoNT/A injections
showed similarly persistent structural abnormalities. In
spite of the clear functional recovery, the abnormalities
of the anatomical features of motor innervation were still
present months after a second or, as illustrated in Fig. 13,
a third injection.
Atlowmagniﬁcations,itwasclearthatthecentralband
ofinnervationwasmuchwiderininjectedmusclesthanin
uninjected contralateral controls (Fig.13A and C). In the
examplesillustrated(uninjectedcontroland124daysafter
BoNT/A)theinnervationbandismorethantwiceaswide
asnormal,andthiswastypicalofthemusclesweobserved.
Wedidnotattempttoquantifythisincreaseindetail,orto
establish whether the width increased progressively with
the number of injections.
At higher magniﬁcation, it was clear that the individual
NMJs were also often very abnormal. Some examples
from muscles at 124days after a third injection of
BoNT/A are shown in Fig.13D–G. These show both
persisting individual sprouts (Fig.13D) and multiple
lateral sprouts (Fig.13F and G). At longer times after the
ﬁnal injection of BoNT/A (223days), a number of very
abnormalNMJspersisted(Fig.13H–K).Thesewereoften
associated with lateral branches of long myelinated axons
coursing along the muscle ﬁbres (Fig.13I). Although
NMJs from uninjected contralateral muscles were often
rather complex (Fig.13B), probably a result of the
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Figure 11. Response to repetitive stimulation of uninjected
control NMJs and NMJs 4 months after recovery from BoNT/A
In each case trains of 100 stimuli were given at frequencies from 1 to
100 Hz and the peak amplitudes of the resulting EPPins are plotted.
For both control (A) and recovered (B and C) NMJs, stimulation at 50
and 100 Hz caused initial facilitation followed by substantial
depression. At 1–20 Hz, there was depression but no facilitation. The
graphs show averaged pooled data from 75 NMJs from 5 uninjected
control mice (A), from 45 NMJs from 3 mice 4 months after a single
injection (B), and from 45 NMJs from 3 mice after a 2nd injection,
given 4 months after the ﬁrst (C).
advancedage(476days)(Barker&Ip,1966;Tuffery,1971;
Cardasis&LaFontaine,1987),theyonlyrarelyhadsprouts.
Insummary,itisclearthatalthoughsubstantialrecovery
ofquantalreleaseoccursinETAmusclesaftertwoorthree
injection of BoNT/A, striking structural abnormalities of
themotoraxonsandNMJsmaypersistformanymonths.
Discussion
Summary of main results
An important ﬁnding of our study of the mouse ETA is
that the region of the original NMJ plays a much greater
role in the initial recovery from the blocking effects of
BoNT/A than previously thought. In fact, our estimates
of quantal release from new synaptic contacts suggest that
they play a relatively minor role in functional recovery. A
second important ﬁnding is that after several exposures
to BoNT/A, while neuromuscular transmission can be
restored to near normal levels, it does so more slowly than
after a single exposure and is accompanied by profound
abnormalities in the structure of the intramuscular nerve
and the NMJs. These ﬁndings raise some concerns about
the cumulative effects of repeated exposure to BoNT/A
in a therapeutic or cosmetic context. At the same time,
they attest to the remarkable adaptive plasticity of the
mammalian NMJ.
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Figure 12. Recovery of quantal content at mouse ETA NMJs
after one, two or three injections of BoNT/A
Injections were given at intervals of 3–4 months. Time is shown after
the ﬁnal injection. Note that recovery after 2 and 3 injections is slower
than after a single injection. Each point indicates averaged values of
pooled data from a number of ﬁbres, typically 10, in one mouse.
Regression lines have been drawn through the data for each number
of injections: dotted, 1 injection; dashed, 2 injections; continuous, 3
injections. Statistical analysis is described in the text.
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Initial recovery
Timing of recovery. The time course of recovery of
quantal release after administration of BoNT/A is similar
Figure 13. Abnormal structural aspects of motor innervation after three injections of BoNT/A
Nerves (green) immunolabelled with anti-NFP and anti-synaptophysin, AChR (red) labelled with R-BgTx). A and C,
low magniﬁcation (scale bar in A also applies to C) views of normal (saline injected) ETA and an ETA from a mouse
of approximately the same age (476 days) which had received 3 injections of BoNT/A at approximately 3-monthly
intervals. The band containing NMJs is about twice as wide as normal indicating persisting abnormal distribution
of NMJs. B and D–G, higher magniﬁcation views (scale bar in B applies to all 5 panels). B is from an uninjected
muscle showing NMJ structure typical of mice of this age, consisting of a compact cluster of spot-like regions.
D–G show a selection of NMJs from injected muscles, 124 days after the 3rd injection. While the NMJ in E has a
structure within the normal range, the others show synaptic spots arising from ultraterminal sprouts (D) or short
lateral axonal branches (F and G) that are very rarely seen in normal muscles. H–K, ETA muscle 223 days after 3rd
injection of BoNT/A. The lower magniﬁcation views (H and I, same magniﬁcation) show axons coursing along the
muscle ﬁbres while the higher magniﬁcation views (J and K, same magniﬁcation) show abnormal distributions of
AChR clusters.
in the ETA to that described for sternomastoid (de Paiva
et al. 1999) but is somewhat faster than that reported for
other mouse muscles (soleus, EDL, LAL) where quantal
content reached 50% of its normal value in 10–14weeks
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(Tonge, 1974; Santafe et al. 2000). In making these
comparisons,itisimportanttobearinmindthatdifferent
preparations of BoNT/A were used, and possibly different
effective doses, and that different methods were used to
estimate quantal content. In spite of these differences, the
time required for all these mouse muscles to recover after
BoNT/Aisroughlysimilartothedurationofeffectiveness
of a single injection in man. It should be noted, however,
that because of the high safety factor for neuromuscular
transmission (Wood & Slater, 2001), patients may sense
signiﬁcant functional recovery when transmission is still
substantially depressed. What of course differs between
mice and men is the fraction of the lifespan required for
recovery.
Several studies have noticed the ‘weaker’ sprouting
response evoked by BoNT/A in functionally fast muscles
(Duchen, 1970; Brown et al. 1980; Caroni et al. 1997;
Frey et al. 2000). It is reasonable to suppose that that the
pattern of short, high frequency bursts characteristic of
fast motor units (Hennig & Lomo, 1985), which is known
to be particularly effective in suppressing many effects
of muscle inactivity (Windisch et al. 1998), might also
suppress axonal sprouting and thus hinder recovery from
BoNT/A (Brown et al. 1980). However, it is clear from
both our observations of the ETA and previous studies
of the LAL (Juzans et al. 1996a) that rapid and extensive
sprouting can occur in an almost exclusively fast muscle,
and that functional recovery can also be relatively fast. As
discussed below, one possible explanation for this may be
thatfastmusclestendtomakenewsproutswithinthearea
of the original NMJ.
Contribution of new synaptic contacts to recovery. Our
conclusions concerning the role of new synaptic contacts
to functional recovery from BoNT/A differ substantially
from those of the only previous study to investigate this
point (de Paiva et al. 1999; Meunier et al. 2003). Because
theconclusionsofthatstudyhavebeencitedinanumberof
subsequentarticles(Meunieretal.2002;Foranetal.2003;
Dolly & Aoki, 2006; Osborne et al. 2007), it is important
to consider the possible origins of these differences.
de Paiva et al. (1999) used FM1-43 uptake to assess
nerve terminal function. In many situations, a good
correspondencebetweentheintensityofFM1-43labelling
andquantalreleasehasbeendemonstrated(Cochillaetal.
1999). However, in the present situation, this method has
certain limitations. One is its inherent sensitivity. During
the early stages of recovery after BoNT/A, the intensity
of quantal release we observed at the sites of the original
NMJs is only a few per cent of normal. While electro-
physiological recording is capable of detecting the effects
of individual quanta, the ﬂuorescence signals associated
with such low levels of release would be difﬁcult to detect.
Further, it is important to note that the lowest levels of
FM1-43labellingoftheoriginalterminalsdocumentedby
de Paiva et al. remained at 10–25% of the normal value
(seetheirFig.1h;deP aivaetal.1999).Howeverinstudies,
including the present one, where quantal release has been
measured directly, it has initially fallen to less than 1%
of normal. This suggests that the intensity of FM1-43
ﬂuorescence may not accurately reﬂect the low levels of
quantal release that follow BoNT/A intoxication.
AnimportantfurtherassumptionmadebydePaivaetal.
1999 is that the FM1-43 signal from the entire length of
the sprouts reﬂects physiologically signiﬁcant transmitter
release. Only transmitter quanta released within a few
micrometres of AChR clusters can have any impact on
membrane excitation. However, it is clear from de Paiva
et al. and from this study that AChR clusters occupy only
asmallfractionofthetotallengthofthesprouts(cf.Figs3
and13).Thus,whilemembranecyclingmayoccurallalong
thesproutsastheygrowandextendlateralbranches,much
ofthismaynotberelevantforquantalreleaseofACh.Our
electrophysiological approach, while not measuring ACh
release directly, does indicate ‘effective’ release, i.e. that
which leads to membrane depolarization.
The inﬂuence of terminal sprouting on quantal release
from the mammalian NMJs has been investigated in
another context, that of recovery after chronic block of
nerve impulses. Using a cuff containing tetrodotoxin to
blocktheratsciaticnerve,Tsujimotoetal.(1990)observed
an increase in quantal content before any sprouting was
detectable. At later times, the quantal content was no
greater at those NMJs where sprouting had occurred
than where it had not. They concluded that sprouting
and increased quantal content are not causally related
in the conditions of their experiments. By implication,
a mechanism must exist by which quantal content can
be raised within the conﬁnes of the original NMJ. A
similar conclusion was reached in studies of increased
quantal release in the absence of any enlargement of
the NMJ in myasthenia gravis and an animal model of
it (Plomp et al. 1992, 1995). The mechanism of the
up-regulation of quantal release in these situations is
unknown. It is therefore impossible to know whether a
similar mechanism might be responsible for the recovery
of the original NMJs after exposure to BoNT/A. However,
it should be noted that in these other examples there is no
indicationofstructuralalterationstotheproteinsinvolved
inexocytosis,ortotheresultingneedtoreplacethem,that
characterize the response to BoNT/A.
Changes in synaptic events during recovery. Previous
studies of NMJs blocked by BoNT/A have reported an
increase in the number of spontaneous mEPPs with
abnormally large amplitudes and long time courses
(Thesleff & Molgo, 1983; Kim et al. 1984), sometimes
referred to as ‘giant’ or ‘slow’ mEPPs. Much less has been
reported about the properties of evoked EPPs and EPCs.
While it has been stated that the rise time of individual
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evokedEPPsremainednormalduringtherecoveryperiod
(Kim et al. 1984), evidence has also been presented of a
slowingofthedecayphaseofEPCs1weekafterexposureto
BoNT/A (Sellin & Thesleff, 1981). In the present study we
observedastrikingslowingofthetimecourseoftheevoked
responses recorded during recovery. This slowing resulted
from increases in the latency, synaptic delay and the rise
anddecaytimesoftheEPPs.Thesechangesreachedapeak
just as transmission began to be effective and were largely
reversed when the quantal content was still only 20–30%
of normal. It may be that these changes were missed in
earlierstudieswhichconcentratedmoreonchangesinthe
ﬁrst week after exposure to BoNT/A.
The nature of these changes in EPP time course is likely
tobemultifactorial.Boththeprolongedsynapticdelayand
the slower rise time of the EPP suggest alterations of the
releaseprocess.Thesemaywellberelatedtorecoveryfrom
theeffectsofthecleavageofSNAP-25(Sakabaetal.2005).
In addition, there is evidence that during recovery from
BoNT/A, L- and N-type voltage-gated calcium channels
are present in the nerve terminal along with the P/Q-type
channels normally present (Day et al. 1997; Santafe et al.
2000; Pagani et al. 2004). It is possible that the L- and
N-typechannelsarenotascloselyassociatedwiththeactive
zone(Urbanoetal.2003)astheP/Q-channelsandthismay
lead to an increase in latency and/or rise time of the EPP.
Littleisknownaboutthesequenceofeventsinthisprocess
of nerve terminal maturation or how it is regulated.
On the postsynaptic side, the period of inactivity
imposed by the action of BoNT/A almost certainly results
in reduction of AChE activity (Hall, 1973) at the original
synaptic sites and increase in the expression of γ-AChR
subunits and hence slow, ‘fetal’ AChRs (Klarsfeld &
Changeux, 1985; Goldman et al. 1988; Witzemann et al.
1991; Koltgen et al. 1994; Missias et al. 1996). Both of
these postsynaptic changes would be likely to lead to the
prolongation of the falling phase of the EPP. However,
they would not be expected to have a major impact on
the rising phase. AChE appears at new synaptic sites soon
after the sprouts grow out (Duchen, 1970) and would be
expected to hasten the falling phase of synaptic currents
and potentials at the new sites. How, if at all, the slow
EPPsweobservedcorrespondtotheslowmEPPsreported
previously is unclear. Although we found a correlation
between the time courses of EPPs and mEPPs from the
same ﬁbres, the numbers of mEPPs was too small to be
conﬁdent of this relationship.
Itwasparticularstrikingthatmorethanonepopulation
of EPPs could be recorded from some single muscle ﬁbres
(Fig.10).Theveryslowrisetimeofthe‘slow’components
strongly suggests local variations in the properties of the
nerve terminals. It may be that the various synaptic spots,
potentially both new and old, on a given muscle ﬁbre
acquire‘mature’propertiesatdifferenttimes.Theincrease
in quantal content associated with recovery of the ETA
lasts at least 8–10weeks. Previous studies have shown that
axonalsproutsmaycontinuetogrowforasimilarlengthof
time(Juzansetal.1996a;Santafeetal.2000).Itistherefore
likely that new contacts continue to be made throughout
this period, though possibly at a progressively slower rate
as muscle activity returns to normal. This suggests that
synaptic contacts established both early and late in the
recovery process might coexist on the same muscle ﬁbre,
and might have relatively fast and slow EPPs associated
with them.
By the end of the main recovery process, 3–4months
after exposure to BoNT/A, the functional properties of
mouse ETA NMJs that we examined had essentially
returned to normal. The observation that the response
to repetitive stimulation is qualitatively similar to that in
untreatedmice,showingbothrapidtransientpotentiation
at high frequency followed by depression, suggests that
both calcium dynamics and synaptic vesicle pools in the
motor nerve terminals recover their normal properties
aftertreatmentwithBoNT/A.Notenoughexperimentsof
thiskindwereperformedtoknowwhetherthedifferences
between the curves in Fig. 11 represent statistically
signiﬁcant differences.
Recovery from multiple exposures to BoNT/A
Ours is the only study we are aware of that has
examinedsystematicallythestateofneuromusculartrans-
mission after multiple exposures to BoNT/A. Although
the extended duration of these experiments means that
thesampleswerenotlarge,itisnonethelessclearthatvery
substantial recovery is possible even after three exposures.
Thisisconsistentwiththeclinicalobservationsthatunder-
lie the need for multiple injections to maintain effective
weakeningofdystonicmuscles(Jankovic&Hallett,1994).
However, there is a clear indication from our data that
recoveryaftertwoandthreeexposuresisslower,andmore
variable, than after an initial exposure.
In contrast to the eventual success of functional
recovery, striking structural abnormalities persisted long
after multiple exposures to BoNT/A. This indicates that,
at least in the mouse ETA, an appreciable number of
the new contacts made during initial recovery survive
the withdrawal process that has been noted by previous
authors (Duchen, 1970; de Paiva et al. 1999). Whether
the plasticity of these ‘extended’ nerve branches when
confrontedwithfurtherexposurestoBoNT/Aisasgreatas
when BoNT/A is ﬁrst given is unclear. It is also important
tonotethattheanimalsreceivingmultipleinjectionswere
generally older when the muscles were examined than
those receiving only one. How, if at all, the ageing process
inﬂuences NMJ plasticity remains an important question
for the future.
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Biological and clinical implications
Ourresultsindicatethatrecoveryofevokedquantalrelease
can occur in the region of the original NMJ at an early
stage of the response to BoNT/A. In addition, they show
that there are similarities in the sequence of events in
the maturation of the release process at the original NMJ
and at more remote ‘new’ contacts. The structural basis
of the early release we observed from the region of the
originalNMJisnotclear.Onepossibilityisthattheoriginal
contacts recover more rapidly than previously thought.
Alternatively,orinaddition,itmaybethatnewsproutsand
functional contacts are made within the original synaptic
region as well as more remotely. Local remodelling of the
NMJ is well-documented in a number of situations. It
occurs during normal ageing (Barker & Ip, 1966; Arizono
et al. 1984) and is very marked at NMJs on muscle ﬁbres
that regenerate after damage (Duchen et al. 1974; Lyons &
Slater, 1991). Although the molecular basis of this local
plasticity is not understood in detail, up-regulation of
surface adhesion molecules is likely to play a part. In
support of this is the observation that overexpression of
NCAM in mouse muscle leads to sprouting both within
andawayfromtheNMJs(Walshetal.2000).Sincemuscle
inactivity leads to up-regulation of NCAM (Cashman
et al. 1987), it is likely to occur after exposure to BoNT/A
and may therefore play an important part in stimulating
both local and remote sprouting. If, as seems likely from
available evidence (Duchen, 1970; Brown et al. 1980; Frey
etal.2000),thedetailedpatternofrecoverydiffersbetween
species and muscles, it will be of interest to learn which
factors determine the balance between reinnervation of
the original NMJ and the formation of new, often quite
remote, synaptic contacts in different muscles.
A striking feature of NMJ remodelling is that it often
results in NMJs with abnormal structure but substantially
normal function. This is known to be true in two of the
examples cited above (mdx mice, NCAM up-regulation).
The ability of the NMJ to maintain an adequately
functional state in the face of structural disruption is
further supported by observations of NMJs after multiple
exposures to BoNT/A both in animals, as presented here,
and in humans (Holds et al. 1990) (Pang et al. in pre-
paration). Together with other evidence of the ability of
the mammalian NMJ to regulate quantal output to match
need(e.g.Plompetal.1994,1995),theseﬁndingsattestto
the remarkable adaptive plasticity of the NMJ. In spite of
its biological importance, almost nothing is known about
the nature of this form of plasticity.
Although we found that NMJs in the mouse ETA could
recoverfunctionaftermultipleexposurestoBoNT/A,there
wasclearindicationthattheprocesseventuallybecameless
effective. Thus, there was an accumulation of structurally
abnormal NMJs and functional recovery was slower after
an initial exposure. These observations suggest that the
NMJ does not return to a fully normal state after repeated
exposuretoBoNT/A.Thisshouldsoundanoteofcaution
for those using BoNT/A as the basis for clinical and
cosmetic treatments.
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